Eur Rev Med Pharmacol Sci 2022; 26 (4): 1073-1074
DOI: 10.26355/eurrev_202202_28095

Should we still consider colchicine in treating patients with COVID-19?

O.N. Putra, S. Sofia, A. Widad, C.R. Oktaviani

Department of Clinical Pharmacy, Study Program of Pharmacy, Hang Tuah University, Surabaya, East Java, Indonesia. oki.nugraha@hangtuah.ac.id

Free PDF Download

To cite this article

O.N. Putra, S. Sofia, A. Widad, C.R. Oktaviani
Should we still consider colchicine in treating patients with COVID-19?

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 4
Pages: 1073-1074
DOI: 10.26355/eurrev_202202_28095

Keywords Related articles:

  1. Assessment of anxiety level and sleep quality of medical staff treating patients with COVID-19
  2. Can we still consider treatment with colchicine effective in SARS-COV-2 infection? Systematic review, meta-analysis, and trial sequential analysis
  3. Epidemiological analysis of 18 patients with COVID-19
  4. Ozone therapy may be an option for COVID-19 patients
  5. Spatiotemporal changes of CT manifestations in 110 patients with COVID-19 pneumonia